Related Experiment Video
Updated: Mar 22, 2026
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
945
Serum adropin level and ENHO gene expression in systemic sclerosis
Servet Yolbas1, Murat Kara2, Musa Yilmaz3
1Department of Rheumatology, Faculty of Medicine, Firat University, 23119, Elazig, Turkey.
Clinical Rheumatology
|April 16, 2016
Summary
Serum adropin levels were elevated in systemic sclerosis (SSc) and Behçet
Area of Science:
- Endocrinology
- Immunology
- Genetics
Background:
- Adropin, a protein encoded by the ENHO gene, influences angiogenesis and apoptosis.
- Systemic sclerosis (SSc) is a condition marked by vasculopathy, inflammation, and fibrosis.
- Investigating adropin's role in SSc may reveal new insights into its pathogenesis.
Purpose of the Study:
- To determine serum adropin levels and ENHO gene expression in patients with SSc.
- To compare these levels with those in Behçet's disease (BD) and healthy controls (HC).
- To explore associations between adropin/ENHO and disease characteristics in SSc and BD.
Main Methods:
- Serum adropin levels were measured using ELISA.
- ENHO gene expression was analyzed in peripheral blood mononuclear cells via real-time PCR.
- Participants included 27 SSc patients, 39 BD patients, and 20 HC.
Main Results:
- Serum adropin levels were significantly higher in SSc and BD groups compared to HC.
- No significant differences in ENHO gene expression were observed among the groups.
- Adropin levels and ENHO expression did not correlate with SSc subtypes, disease activity, or severity.
Conclusions:
- Elevated serum adropin may be a general response to chronic inflammation, not specific to SSc.
- Further research is required to elucidate adropin's exact function in SSc.
- ENHO gene expression showed a negative correlation with triglyceride levels in BD patients.
